Skip to main content
. 2013 Mar 11;31(13):1662–1668. doi: 10.1200/JCO.2012.45.9453

Table 3.

Multivariate Analysis of PFS

Covariate Hazard Ratio 95% CI P
Treatment arm
    R-BEAM 1.00 .66
    B-BEAM 1.08 0.76 to 1.54
Disease status at transplantation
    CR 1.00 .008
    Not in CR 1.63 1.14 to 2.33

Abbreviations: B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; CR, complete remission; PFS, progression-free survival; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.